Needham & Company LLC Reiterates “Buy” Rating for Esperion Therapeutics (NASDAQ:ESPR)

Needham & Company LLC reiterated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a report published on Friday morning, Benzinga reports. They currently have a $8.00 price target on the biopharmaceutical company’s stock.

Several other equities analysts have also recently commented on the stock. Bank of America cut shares of Esperion Therapeutics from a neutral rating to an underperform rating and reduced their price objective for the company from $2.90 to $2.50 in a research note on Thursday, June 20th. StockNews.com cut shares of Esperion Therapeutics from a strong-buy rating to a buy rating in a research note on Friday, May 17th. Finally, HC Wainwright reaffirmed a buy rating and set a $16.00 price objective on shares of Esperion Therapeutics in a research note on Friday. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of Hold and a consensus target price of $8.83.

Esperion Therapeutics Trading Up 5.4 %

Shares of NASDAQ:ESPR opened at $2.34 on Friday. The company has a 50 day moving average of $2.32 and a 200 day moving average of $2.41. The stock has a market cap of $443.34 million, a P/E ratio of -2.36 and a beta of 1.02. Esperion Therapeutics has a 12 month low of $0.70 and a 12 month high of $3.40.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported $0.34 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.42. The firm had revenue of $137.74 million for the quarter, compared to analysts’ expectations of $53.11 million. On average, equities analysts forecast that Esperion Therapeutics will post -0.05 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Esperion Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Spire Wealth Management grew its stake in Esperion Therapeutics by 69.2% in the 4th quarter. Spire Wealth Management now owns 17,767 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 7,267 shares in the last quarter. Private Portfolio Partners LLC purchased a new position in Esperion Therapeutics in the 4th quarter worth approximately $30,000. Herbst Group LLC purchased a new position in Esperion Therapeutics in the 1st quarter worth approximately $28,000. Summit Financial LLC grew its stake in Esperion Therapeutics by 66.8% in the 1st quarter. Summit Financial LLC now owns 25,864 shares of the biopharmaceutical company’s stock worth $69,000 after buying an additional 10,355 shares in the last quarter. Finally, PSI Advisors LLC lifted its holdings in shares of Esperion Therapeutics by 161.5% in the 4th quarter. PSI Advisors LLC now owns 17,000 shares of the biopharmaceutical company’s stock worth $51,000 after acquiring an additional 10,500 shares during the last quarter. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.